Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Trinity Biotech plc (ADR) (TRIB) A Good Stock To Buy?

Page 1 of 2

Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the big brokerage houses don’t follow. Small caps are where they can generate significant out-performance. These stocks have been on a tear since the end of June, outperforming large-cap index funds by more than 10 percentage points. That’s why we pay special attention to hedge fund activity in these stocks.

Trinity Biotech plc (ADR) (NASDAQ:TRIB) was in 14 hedge funds’ portfolios at the end of the third quarter of 2016. TRIB investors should pay attention to an increase in hedge fund sentiment of late. There were 13 hedge funds in our database with TRIB holdings at the end of the previous quarter. At the end of this article we will also compare TRIB to other stocks including CONN’S, Inc. (NASDAQ:CONN), Bridgepoint Education Inc (NYSE:BPI), and Natural Health Trends Corp. (NASDAQ:NHTC) to get a better sense of its popularity.

Follow Trinity Biotech Plc (NASDAQ:TRIB)
Trade (NASDAQ:TRIB) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

investment, accounting, growth, bank, banking, concept, data, benefit, business, wealth, profit, rate, capital, trade, foreign, market, bill, chart, euro, world, background,

violetkaipa/Shutterstock.com

What does the smart money think about Trinity Biotech plc (ADR) (NASDAQ:TRIB)?

Heading into the fourth quarter of 2016, a total of 14 of the hedge funds tracked by Insider Monkey held long positions in this stock, a rise of 8% from the previous quarter. The graph below displays the number of hedge funds with bullish positions in TRIB over the last 5 quarters, which has remained steady in 2016 after a steep decline at the end of 2015. So, let’s find out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

HedgeFundSentimentChart (105)

Of the funds tracked by Insider Monkey, Richard S. Meisenberg’s ACK Asset Management has the largest position in Trinity Biotech plc (ADR) (NASDAQ:TRIB), worth close to $13 million, corresponding to 3.9% of its total 13F portfolio. Sitting at the No. 2 spot is Park West Asset Management, led by Peter S. Park, holding an $11.3 million position; the fund has 1% of its 13F portfolio invested in the stock. Some other hedge funds and institutional investors that hold long positions comprise Richard Mashaal’s RIMA Senvest Management, Chuck Royce’s Royce & Associates,and Peter S. Park’s Park West Asset Management. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2